Collaboration with nation's largest military medical center focuses on bioAffinity Technologies' pipeline of solutions to address debilitating respiratory diseases

Study to explore the potential for proprietary flow cytometry+AI diagnostic tests targeting the asthma and COPD treatment market estimated at $92 billion1

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a pilot study with Brooke Army Medical Center (BAMC) to evaluate the Company's proprietary tests under development to identify specific inflammatory biomarkers for asthma and chronic obstructive pulmonary disease (COPD). The study could lead to the development of diagnostic tests designed to help align patients with the most effective treatments and help monitor the drugs' effectiveness over time.

The research collaboration with BAMC builds on bioAffinity Technologies' research pipeline, leveraging its proprietary flow cytometry+AI technology to develop precision diagnostics and treatments for common airway diseases by assessing the extent and type of lung inflammation.